🟢 Lantern Pharma is trading 18.5% up in pre-market with no confirmed company announcement

Lantern Pharma is trading at $0.76, up 18.51%, with no confirmed company announcement explaining the sharp pre-market gain.

• The latest notable company-related headline was coverage of an LP-284 patent notice, originally announced September 22, so it is not a new catalyst.
• The move is opposite the supplied weak biotech-sector context; available evidence does not establish whether trading activity or another catalyst explains the rise.